Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.

Among the presentation highlights are several new post-hoc analyses of the pivotal PULSAR trial for EYLEA HD in wet age-related...

Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoin...

Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients ach...

The results were presented today, in collaboration with Regeneron, for the first time at the 2024 European Respiratory Society ...

Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and d...

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $101...